Sunday, September 7, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Bitcoin

S&P 500 Snub Deals Major Blow to MicroStrategy’s Bitcoin Ambitions

Robert Sasse by Robert Sasse
September 6, 2025
in Bitcoin, Blockchain, Crypto Stocks, S&P 500
0
Strategy Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

In a move that stunned market participants, the committee overseeing the S&P Dow Jones Indices rejected MicroStrategy’s inclusion in the benchmark index this past Friday. The business intelligence firm, which recently rebranded as Strategy Inc., was passed over despite meeting all formal technical requirements for admission, including sufficient market capitalization and four consecutive profitable quarters. Instead, the coveted spots were awarded to Robinhood, AppLovin, and Emcor Group.

This exclusion represents a significant setback for the company. Inclusion would have compelled index-tracking funds to purchase its stock, and market experts had projected potential inflows of approximately $16 billion. The disappointment triggered an immediate sell-off, sending the company’s shares tumbling in after-hours trading.

A High-Stakes Strategy Faces Scrutiny

The decision is widely interpreted as a pointed critique of MicroStrategy’s singular focus. While the traditional financial market shows it a cold shoulder, the company continues to aggressively pursue its Bitcoin acquisition strategy. It now holds a colossal 214,400 Bitcoin, a stash valued at over $70 billion and the largest of any publicly traded corporation worldwide.

Should investors sell immediately? Or is it worth buying Strategy?

However, this massive expansion has come at a considerable cost. To fund its relentless Bitcoin purchases, MicroStrategy has systematically diluted existing shareholders through substantial secondary stock offerings. The company recently broke its own promise not to sell shares below a specific valuation multiple, underscoring the immense pressure to continue funding its crypto acquisitions.

Growing Disconnect Between Assets and Valuation

A particularly troubling trend for investors is the growing divergence between the company’s Bitcoin holdings and its stock performance. Although the Bitcoin treasury has more than doubled since the stock’s peak in late 2024, the share price has failed to keep pace. Consequently, each share now represents a significantly larger underlying Bitcoin value, a fact the market has so far refused to reward appropriately.

The S&P committee’s verdict appears to signal deep institutional skepticism regarding the sustainability of MicroStrategy’s high-risk, crypto-centric business model. The subsequent downward trend in the stock price following the news highlights a critical moment of reassessment for the pioneering Bitcoin corporate holder.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from September 6 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 6.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Robinhood Stock
Crypto Stocks

Robinhood’s S&P 500 Inclusion: A Watershed Moment for Fintech

September 6, 2025
MSCI World ETF Stock
ETF

The Hidden Tech Concentration Within a Global ETF

September 6, 2025
Owens, Minor Stock
Analysis

Owens & Minor Faces Dual Challenge After Index Removal

September 6, 2025
Next Post
Eli Lilly Stock

Lilly's Oncology Breakthrough: Cancer Drug Designation Signals Pipeline Strength

OceanFirst Stock

OceanFirst's Strategic Moves Amid Mixed Financial Performance

US Physical Therapy Stock

Mixed Signals Emerge as US Physical Therapy Posts Record Results Amid Insider Sales

Recommended

BLDR stock news

Prominent Financial Firm SG Americas Securities LLC Increases Stake in Builders FirstSource as Company’s Potential Growth Trajectory Shines

2 years ago
Science Applications Stock

Institutional Investors Defy Cautious Analyst Stance on Science Applications

1 week ago
Green energy

Breakthrough in Carbon Capture Technology by ESG Clean Energy Subsidiary of Camber Energy

2 years ago
Tesla Stock

Tesla’s Expansion Hits Speed Bumps in Key Markets

4 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple BA BioNTech Broadcom C Coinbase DIS Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSFT NIO Nvidia Opendoor Oracle Palantir PayPal Pepsi PLTR Realty Income Red Cat Robinhood Rocket Lab USA SMCI Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Lilly’s Oncology Breakthrough: Cancer Drug Designation Signals Pipeline Strength

S&P 500 Snub Deals Major Blow to MicroStrategy’s Bitcoin Ambitions

Oxford Lane Capital Implements Reverse Stock Split to Address Share Price Decline

Kingsway Financial Services: A Tale of Conflicting Investor Sentiment

Mixed Signals Weigh on Ultrapar’s Stock Performance

Can Illumina’s Bold Protein Analysis Strategy Reverse Its Market Slide?

Trending

TG Therapeutics Stock
Analysis

TG Therapeutics Stock: Riding a Wave of Commercial Success

by Robert Sasse
September 6, 2025
0

TG Therapeutics is demonstrating extraordinary momentum, largely driven by the remarkable performance of its flagship therapy. While...

US Physical Therapy Stock

Mixed Signals Emerge as US Physical Therapy Posts Record Results Amid Insider Sales

September 6, 2025
OceanFirst Stock

OceanFirst’s Strategic Moves Amid Mixed Financial Performance

September 6, 2025
Eli Lilly Stock

Lilly’s Oncology Breakthrough: Cancer Drug Designation Signals Pipeline Strength

September 6, 2025
Strategy Stock

S&P 500 Snub Deals Major Blow to MicroStrategy’s Bitcoin Ambitions

September 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • TG Therapeutics Stock: Riding a Wave of Commercial Success September 6, 2025
  • Mixed Signals Emerge as US Physical Therapy Posts Record Results Amid Insider Sales September 6, 2025
  • OceanFirst’s Strategic Moves Amid Mixed Financial Performance September 6, 2025

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com